What is VOQUEZNA®?
VOQUEZNA® (vonoprazan) is a first-in-class potassium-competitive acid blocker (PCAB) used to treat gastrointestinal diseases, including GERD and H. pylori infection.
Yanuki
ARTICLE DETAIL
VOQUEZNA® Receives 10-Year Exclusivity Extension from FDA | Femtech Market Growth to $26 Billion by 2033: Key Insights and Opportunities | Preparing for Daylight Saving Time 2026: What You Need to Know | Oscar-Nominated Directors Highlight Workers at a Women's Health Clinic in 'The Devil Is Busy' | Trump Spotted with Rash on Neck: Possible Causes and Theories | Olympic Village Condom Shortage: A Hot Topic at the 2026 Winter Games | Talcum Powder and Cancer: Unveiling the Connection | Drug-Resistant Typhoid Fever: An Ancient Killer Returns | RFK Jr.'s CDC Panel to Discuss Covid Vaccine Injuries | VOQUEZNA® Receives 10-Year Exclusivity Extension from FDA | Femtech Market Growth to $26 Billion by 2033: Key Insights and Opportunities | Preparing for Daylight Saving Time 2026: What You Need to Know | Oscar-Nominated Directors Highlight Workers at a Women's Health Clinic in 'The Devil Is Busy' | Trump Spotted with Rash on Neck: Possible Causes and Theories | Olympic Village Condom Shortage: A Hot Topic at the 2026 Winter Games | Talcum Powder and Cancer: Unveiling the Connection | Drug-Resistant Typhoid Fever: An Ancient Killer Returns | RFK Jr.'s CDC Panel to Discuss Covid Vaccine Injuries
Health / Pharmaceuticals
VOQUEZNA® Receives 10-Year Exclusivity Extension from FDA
Phathom Pharmaceuticals (Nasdaq: PHAT) announced that the FDA has approved its Citizen Petition, granting VOQUEZNA® (vonoprazan) tablets 10 years of New Chemical Entity exclusivity, extending until May 3, 2032. This decision corrects the Or...
Key Insights
- The FDA has granted VOQUEZNA® (vonoprazan) tablets market exclusivity until May 3, 2032.
- VOQUEZNA® is a first-in-class potassium-competitive acid blocker (PCAB) used to treat heartburn associated with Non-Erosive GERD and Erosive GERD, as well as H. pylori infection.
- This exclusivity protects Phathom Pharmaceuticals' investment and market position for VOQUEZNA®.
- Why this matters: This decision ensures that Phathom Pharmaceuticals will have a longer period to capitalize on its innovative treatment, potentially leading to increased revenue and further research in gastrointestinal therapies.
In-Depth Analysis
On June 6, 2025, Phathom Pharmaceuticals announced a favorable decision from the FDA regarding VOQUEZNA®'s market exclusivity. The FDA approved Phathom's Citizen Petition, ensuring that VOQUEZNA® (vonoprazan) tablets will have 10 years of New Chemical Entity exclusivity, lasting until May 3, 2032. This exclusivity period is crucial for Phathom as it commercializes VOQUEZNA® for treating gastrointestinal diseases.
VOQUEZNA® is a first-in-class potassium-competitive acid blocker (PCAB) used for:
- Relief of heartburn associated with Non-Erosive GERD in adults.
- Healing and maintenance of healing of Erosive GERD in adults.
- Treatment of H. pylori infection in adults (as part of VOQUEZNA® TRIPLE PAK® and VOQUEZNA® DUAL PAK®).
This FDA decision provides Phathom Pharmaceuticals with a significant competitive advantage, protecting their market position and encouraging further investment in gastrointestinal treatments. Investors and patients alike benefit from the assurance of continued availability and development of this innovative therapy.
FAQ
What does the FDA exclusivity mean for Phathom Pharmaceuticals?
The 10-year exclusivity means that Phathom Pharmaceuticals will have exclusive rights to market VOQUEZNA® until May 3, 2032, without competition from generic versions.
Takeaways
- VOQUEZNA® has received a 10-year market exclusivity extension from the FDA, ensuring its availability until 2032.
- This medication is used to treat common gastrointestinal issues like GERD and H. pylori infection.
- Phathom Pharmaceuticals will continue to develop and commercialize VOQUEZNA®, benefiting patients and investors.
Discussion
What are your thoughts on the FDA's decision to extend VOQUEZNA®'s exclusivity? Share this article with others who need to stay ahead of this trend!
Sources
Disclaimer
This article was compiled by Yanuki using publicly available data and trending information. The content may summarize or reference third-party sources that have not been independently verified. While we aim to provide timely and accurate insights, the information presented may be incomplete or outdated.
All content is provided for general informational purposes only and does not constitute financial, legal, or professional advice. Yanuki makes no representations or warranties regarding the reliability or completeness of the information.
This article may include links to external sources for further context. These links are provided for convenience only and do not imply endorsement.
Always do your own research (DYOR) before making any decisions based on the information presented.